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Influenza vaccination is a common approach to prevent seasonal and pandemic
influenza. Pre-existing antibodies against close viral strains might impair antibody
formation against previously unseen strains–a process called original antigenic sin. The
role of this pre-existing cellular immunity in this process is, despite some hints from
animal models, not clear. Here, we analyzed cellular and humoral immunity in healthy
individuals before and after vaccination with seasonal influenza vaccine. Based on
influenza-specific hemagglutination inhibiting (HI) titers, vaccinees were grouped into
HI-negative and -positive cohorts followed by in-depth cytometric and TCR repertoire
analysis. Both serological groups revealed cross-reactive T-cell memory to the vaccine
strains at baseline that gave rise to the majority of vaccine-specific T-cells post
vaccination. On the contrary, very limited number of vaccine-specific T-cell clones was
recruited from the naive pool. Furthermore, baseline quantity of vaccine-specific central
memory helper T-cells and clonotype richness of this population directly correlated
with the vaccination efficacy. Our findings suggest that the deliberate recruitment of
pre-existing cross-reactive cellular memory might help to improve vaccination outcome.
Keywords: influenza vaccination, vaccination efficacy, pre-existing cross-reactive T-cells, central memory T-cell,
clonotype diversity
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INTRODUCTION
Influenza infection is a major cause of acute respiratory
infections (1, 2). While healthy individuals manage the infection
efficiently, several groups, including elder, immunosuppressed,
and chronically ill individuals, have a significant risk of prolonged
and complicated infection course and high mortality (2, 3).
Vaccination with trivalent inactivated vaccine (TIV) or
live attenuated vaccine (LAV) is the common approach
to raise protective antibody titers against influenza and is
generally accepted as the most relevant protection factor (4,
5). However, it is not rare that the post vaccination antibody
levels are insufficient. Even though several clinical conditions
are associated with low vaccination efficacy (e.g., chronic
inflammatory and metabolic disorders, immune deficiencies),
the scenario of insufficient or failed vaccination also affects the
healthy population (6–8).
The exact prerequisites and correlates of efficient vaccination
are not completely understood so far but have been attributed
to the vaccine origin, its composition and application mode (9–
14). In case of a primary immune response the contact with
previously unseen pathogenic antigens leads to an inflammatory
process and the recruitment of T- and B-cells from naive pools.
Besides generation of effector cells this leads to formation of
the immune memory, both cellular and humoral. In case of a
secondary immune response, pre-existing memory B- and T-
cells promptly proliferate, differentiate and perform numerous
effector functions, resulting in a rapid raise of antibodies titers
and pathogen clearance. For influenza however, the situation
is somewhat special. The previous contacts with influenza
leave long-lasting and sometimes life-long cellular and humoral
immunity. However, due to antigenic drift and shift new viral
strains are continuously created which are no longer recognized
by the pre-existing memory, what helps the virus to bypass the
pre-existing immunity (15–18). The exact role of pre-existing
immune memory in the development of sufficient protection
against novel epitopes is not clear, yet. Numerous findings
indicate that it can be detrimental and lead to impaired formation
of neutralizing antibody against previously unseen influenza
strains. This phenomenon known as the original antigenic sin
(OAS) was initially linked to the pre-existing cross-reactive
antibodies and cognate memory B-cells (19, 20). However, the
role of pre-existing cross-reactive T-cells in an insufficient and
failed immune response against novel influenza strains was
inferred from the studies on Dengue virus and mouse LCMV
(21, 22). This was further strengthened by several reports
on the suppression of naive and follicular influenza-specific
helper T-cells by the pre-existing cross-reactive memory (23,
24). However, new findings show that pre-existing influenza-
specific memory, both cellular and humoral, is not always
detrimental but on the contrary might be helpful in terms
of vaccination efficacy and protection against natural infection
(25, 26). One report showed that the pre-existing cross-reactive
memory CD4 specific to highly conserved internal influenza
virus proteins are sufficient to alleviate influenza infection in
a human inoculation model (27). However, data on the role
of pre-existing memory against highly variable hemagglutinin
(HA) and neuraminidase (NA) induced by vaccination are
very limited.
The goal of the current study was to elucidate the generation
of influenza-specific helper T-cells upon vaccination with novel,
previously unexperienced strains and to unravel their role in the
formation of humoral immunity against novel influenza strains.
MATERIALS AND METHODS
Study Cohort
A total of 15 healthy adult individuals between 24 and 64 years
old were involved in the study. The including criteria were as
follows: 18 years or older, no previous influenza vaccination with
the strains from the current composition (seasonal influenza
vaccine 2011/2012) and/or no confirmed influenza infections in
the past three years, no acute or chronic diseases, no known
allergy to vaccine components, no pregnancy, good general
health condition, written informed consent.
Vaccination and Sample Collection
The vaccination was performed intramuscularly by a study
physician with the trivalent influenza vaccine (Mutagrip
2011/2012 Sanofi-Pasteur). The vaccine was composed of
A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2),
B/Brisbane/60/2008 according to WHO recommendation. 50ml
venous blood was drawn at day 0, 7, 14, and 21 post vaccination
using Lithium-Heparin Vacutainers (BD Biosciences) and
processed immediately.
Hemagglutination Inhibition Assay
Influenza-specific antibody titers were measured by a standard
hemagglutination inhibition (HAI) assay, using vaccine strains
(s. vaccine composition) and turkey hen erythrocytes (28).
Baseline (day 0) and post vaccination (day 21) sera were tested
simultaneously in duplicates and the antibody titers estimated.
Baseline seronegativity was defined by a HAI titer <10 (29).
For statistical evaluation the combined vaccination efficacy for
three vaccine components was calculated as the sum of the
binary logarithm fold change (1LF) between day 21 and baseline
according to the formula:
1LF =
3∑
c=1
log2
(
titer
(
c, day21
)
titer
(
c, day0
)
)
,
where the sum ranges over the three components c.
PBMC Preparation
Peripheral blood mononuclear cells (PBMCs) were isolated
by gradient centrifugation with Ficoll-Paque Plus (GE
Healthcare). PBMCs were re-suspended in complete medium
(RPMI/10%FCS/Penicillin/Streptomycin, all from Gibco).
Flow Cytometric Assessment and Isolation
of Influenza-Specific Helper T-Cells
Frequency, cytokine production and phenotype analysis of the
influenza-specific helper T-cells was done after overnight PBMC
stimulation with the vaccine (at least 10µg/mL of HA from
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every strain). As negative and positive controls, PBMC were
incubated alone or with staphylococcal enterotoxin B (1µg/ml,
Sigma-Aldrich). Brefeldin A was added after 2 h of stimulation
(10µg/mL, Sigma-Aldrich). At the end of the stimulation PBMC
were harvested, stained for surface, and intracellular markers
using FACS-Lysing and FACS-Perm Solution (BD Biosciences),
and analyzed on BD Fortessa flow cytometer (BD Biosciences).
Influenza-specific helper T-cells were isolated after overnight
PBMC stimulation with the vaccine (10µg/mL of HA from
every strain) and human anti-CD40 antibodies (clone HB14,
Miltenyi Biotec). Live sorting was done on BD FACS Aria
(BD Biosciences) with sorting strategy provided in Figure S2.
The following subsets were enriched with high purity: naive
(CD45RA+CCR7+), central memory (CM, CD45RA-CCR7+)
and effector (Eff, CD45RA-CCR7-). Following antibodies were
used for the cytometric analysis and sorting: CD3 eFluor
650 (HIT3a, eBioscience), CD4 QDot 565 (OKT4, Biolegend,
in-house fluorochrome coupling), CD8 QDot 525 (RPT-
T8, Biolegend, in-house fluorochrome coupling), CCR7 FITC
(G043H7, Biolegend), CD45RA eFlour 605 (HI100, eBioscience),
CD154 APC/Cy7 (24-31, Biolegend), CD69 Pe/Cy5 (FN50,
Biolegend), TNFa Pacific Blue (Mab11, Biolegend), IFNg Alexa
Fluor 700 (B27, Biolegend), IL2 Pe (MQ1-17H12, Biolegend),
IL4 Pe/Cy7 (MP4-25D2, Biolegend), IL17 PerCP/Cy5.5 (BL168,
Biolegend), CD19 V500 (HIB19, BD Biosciences), CD27 PerCP-
Cy5.5 (M-T271, Biolegend), IgD FITC (IA6-2, BD Biosciences),
CD20 eFluor 650 (2H7, eBioscience), CD38 Alexa Fluor 700 (HB-
7, Biolegend), CD2/3/4/14/15/34/56/61/235a-biotin (as part of
Pan B Cell Isolation Kit, Miltenyi Biotec), anti-biotin-Vio Blue
(Bio3-18E7, Miltenyi Biotec). Peripheral blood plasmablasts were
gated as CD27++CD38++CD20low/- cells among Lineage-
CD19low/+ population (Figure S1). Absolute cell counts in
peripheral blood were estimated as previously described (30).
Detailed information on the sorted influenza-specific CD4 T-cells
is provided in Table S1.
Clonotype Analysis
The clonotype analysis was performed based on NGS-sequencing
of the TCRβ chain of the FACS-enriched influenza-specific
subsets. The detailed method description with primer
sequences and amplification parameters can be found in
the original publication (31, 32). Briefly, DNA was isolated
using AllPrep DNA Micro Kit (QIagen) and the recombined
TCRβ locus was amplified and processed using Illumina
NGS platform. The raw sequencing data were deposited at
Sequence Read Archive (SRA) with the following BioProject
ID: PRJNA445234.
The raw sequences were processed with subsequent clone
grouping on the nucleotide level using our free open-source
clonotyping platform IMSEQ with analysis parameters provided
in the supplementary Method Information (33). Detailed
information on recovered sequencing reads is provided in
Table S1. For the clonotype richness and overlap analysis,
samples with less than 1,000 raw sequencing reads were
discarded. In order to increase sensitivity of the clonotype
analysis, clonotypes from the memory subsets at baseline (CM
and Eff day 0) were grouped as a common pre-existing memory.
The unique clones from the naive and common memory at
baseline were tracked into the memory subsets post vaccination
and the cumulative frequencies of the corresponding clones
were calculated. Clonotype richness was assessed as the number
of unique clonotype after sample size normalization. For this
reason, subsets were size-normalized to 40,000 raw sequencing
reads (corresponding to the size of the smallest analyzed sample)
and the unique clones grouped. The number of unique clones per
normalized sample represented the value of clonotype richness.
Flow Cytometry and Statistical
Data Analysis
FACS data were analyzed with FlowJo 9.9.3 (TreeStar).
Statistical analysis was performed using GraphPad Prism with
following hypotheses defined beforehand:
1. Serologically exposed and non-exposed cohorts show
different kinetics of peripheral blood B- and influenza-specific
CD4 T-cells,
2. Pre-existing influenza-specific T-cells define vaccination
efficacy in the serologically non-exposed cohort,
3. Origin of influenza-specific CD4 T-cells post vaccination:
baseline naive or cross-reactive memory,
4. Clonotype diversity/richness of the pre-existing influenza-
specific CD4 T-cells define vaccination efficacy in the
serologically non-exposed vaccinees.
Normality distribution was assessed by D’Agostino-Pearson
omnibus or Shapiro-Wilk normality test. In case of normal
distribution parametric t test and Pearson correlation were
calculated; otherwise Mann-Whitney test and Spearman
correlation were performed. Multiple comparisons were adjusted
using the Holm-Sidak approach. P-values<0.05 were considered
significant and designated as following: <0.05 as ∗, <0.01 as ∗∗
and<0.001 as ∗∗∗.
RESULTS
First, we assessed the vaccination efficacy in the cohort of 15
healthy individuals anamnestically not exposed to the natural
influenza or the seasonal vaccination in the previous 3 years.
This way subjects with no recent definite contact with influenza
were preselected. However, despite preselection strategy, further
serology analysis showed preformed hemagglutination inhibiting
(HI)-antibodies to one or several viral strains in 7 out of 15 study
participants at baseline. The vaccinees were therefore stratified
into HI-positive and -negative groups according to the baseline
antibody titers (Table 1). Of note, there were no non-responders
in the study. All individuals developed protective antibody titers
upon vaccination.
HI-Negative Donors Develop a Higher
Plasmablast Response Post
Vaccine Application
In order to determine any difference in the B-cell kinetics in
two serological groups, we analyzed peripheral blood B-cells
including plasmablasts (PB) at baseline and day 7, 14, and 21 post
vaccination by flow cytometry. We did not observe any relevant
changes in B-cell populations except PB. These were defined as
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TABLE 1 | Humoral responses to seasonal influenza vaccine assessed as titers of neutralizing antibodies.
Donor ID Age Gender California D0 Brisbane D0 Perth D0 California D21 Brisbane D21 Perth D21 1LF
#30 26 M 1.00 1.00 1.00 8.32 4.91 4.32 14.55
#37 56 F 4.32 3.32 6.32 5.32 3.32 7.32 2.00
#38 30 M 1.00 1.00 1.00 1.00 6.32 3.32 7.64
#39 59 F 1.00 1.00 1.00 1.00 6.32 6.32 10.64
#40 61 M 1.00 1.00 1.00 4.32 7.91 4.32 13.55
#41 57 M 1.00 3.32 1.00 6.32 5.32 5.91 12.23
#42 64 F 1.00 1.00 1.00 1.00 5.32 11.32 14.64
#43 64 M 1.00 5.32 1.00 5.32 6.32 6.32 10.64
#45 26 M 7.32 5.32 1.00 8.32 9.32 5.32 9.32
#47 29 M 1.00 1.00 1.00 5.32 7.91 9.32 19.55
#51 26 M 1.00 1.00 1.00 7.91 4.32 6.91 16.14
#52 24 M 7.32 6.32 1.00 7.32 6.32 4.32 3.32
#53 26 F 1.00 1.00 1.00 9.91 7.32 7.32 21.55
#54 62 F 1.00 4.32 4.32 6.32 6.32 10.32 13.32
#55 29 F 5.32 4.32 4.32 7.32 7.32 7.91 8.58
Neutralizing antibodies were assessed in HIA at baseline and day 21 post vaccination. Data are shown as binary logarithm of the corresponding dilution titers. 1LF represents the
summary serology change for three influenza strains included in the current vaccine composition.
CD27++CD38++CD20low/- among CD19+/low population
(Figure S1) and analyzed as relative frequencies and absolute
counts per mL whole blood. Significant PB rise at day 7 post
vaccination was present in both groups (Figure 1; HI-positive
group p < 0.01; HI-negative group p < 0.001 and p < 0.01
analyzed as frequencies and counts, correspondingly). The HI-
positive group showed less pronounced changes at day 7, and the
HI-negative group had significantly higher PB (p< 0.05 for both
frequencies and absolute counts). Though the analyses were done
on the whole blood level without further determination of B-cell
antigen specificity, the observed population reflects kinetics of
the influenza-specific PB, as previously shown (34, 35).
Influenza-Specific Central Memory CD4
T-Cells Influence the Vaccination Outcome
in HI-Negative Individuals
In order to analyze the role of CD4 T-cells, peripheral blood
samples from both groups were stimulated with the vaccine
and analyzed by means of multiparameter flow cytometry using
markers of antigen-specific stimulation (31, 36). Analyses were
performed at baseline and day 7, 14, and 21 post vaccination as
CD4 T-cell frequencies and absolute counts (Figure S2).
As anticipated, the HI-positive cohort showed pre-existing
influenza-specific helper T-cells at baseline. This was also the case
in the HI-negative individuals (Figure 2A). The kinetics analysis
showed a significant increase of vaccine-specific CD4 T-cells in
both groups with the peak at day 7 post vaccination (HI-positive
group p < 0.05 for frequencies and absolute counts; HI-negative
group p < 0.001 for frequencies and p < 0.01 for absolute
counts) and a steady decline at later time points (Figure 2A). Of
interest, the HI-negative subjects revealed a significantly higher
magnitude of influenza-specific helper T-cells at the peak of
vaccine-induced response as compared to HI-positive cohort.
While no differences between serological groups were found at
baseline and decline, at day 7 the HI-negative group showed
a significantly higher vaccine-specific response (p < 0.01 for
frequencies and p< 0.05 for cell counts).
We next analyzed the differentiation status of influenza-
specific CD4 T-cells before and after immunization. Using CCR7
and CD45RA the differentiation status of T-cells can be assessed
with division into following subsets: naive (CD45RA+CCR7+),
central memory (CM, CD45RA-CCR7+), effector (Eff, CD45RA-
CCR7-), and terminally differentiated memory T-cells (TEMRA,
CD45RA+CCR7-). Our data showed that the majority of
vaccine-specific T-cells at baseline were of memory phenotype
(Figures 2B–D). In both serological groups, CM dominated over
Eff. Surprisingly, both groups also revealed influenza-specific T-
cells with naive phenotype at baseline (Figure 2D). Though in
absolute minority as compared to memory subsets, naive cells
were present in all participants.
The kinetics of vaccine-specific CM CD4 T-cells in the HI-
positive group showed no significant changes. In the HI-negative
group on the contrary, the changes were highly pronounced.
Compared to baseline, influenza-specific CMCD4T-cells showed
a significant increase with the peak at day 7 with further decline
(Figure 2B; p < 0.001 and p < 0.01 between baseline and day
7 and 14, respectively, for both frequencies and absolute counts;
p< 0.05 between baseline and day 21 for frequency analysis).
Kinetics of vaccine-specific Eff CD4 T-cells resembled the
pattern of unseparated influenza-specific T-cells with the peak
at day 7 and a steady decline thereafter (Figure 2C; HI-positive
group p < 0.01 and p < 0.05 for frequencies and counts; HI-
negative group p< 0.01 for both analyses).
Unexpectedly, vaccine-specific T-cells with naive phenotype
did not show any relevant changes in the course of immunization
and were still present post vaccination (Figure 2D). These cells
showed a truly naive nature as Boolean gating revealed low IL2
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FIGURE 1 | Enhanced peripheral blood plasmablast response in the serologically naive group after vaccine application. Peripheral blood plasmablasts (PB) were
defined as CD27++CD38+ cells among CD19+/low population as relative frequencies and absolute cell numbers per mL peripheral blood. Analyses were performed
at baseline and different time points post vaccination in both HI-negative (n = 8) and HI-positive (n = 7) groups. Parametric t tests with the Holm-Sidak approach for
multiple comparisons were performed. The box plots show median with 25th to 75th percentiles and min to max range (whiskers). P-values are designated as
following: <0.05 as *, <0.01 as ** and <0.001 as ***. The applied gating strategy is provided in Figure S1.
and no effector cytokine production. Memory influenza-specific
T-cells on the contrary produced all measured effector cytokines
(Figures S3A,B). Some donors revealed vaccine-specific TEMRA
CD4 T-cells, however, at extremely low frequencies. This cell
subset was therefore not analyzed further (Figure S2).
We further wondered, which factors influenced the
establishment of influenza-specific humoral immunity. Thus,
we performed a correlation analysis between the amount of
influenza-specific helper T-cells, either complete or further
separated based on different differentiation status, and the
degree of humoral response. We found that in the HI-negative
group the absolute counts of influenza-specific CM T-cells at
baseline correlated significantly with the change in vaccine-
specific antibody titer (Figure 2E; Pearson R = 0.78, adjusted
p = 0.02). We could not identify other correlations in the
HI-negative group; there were no correlations in the HI-positive
group. Taken together, the data presented here show that the
number of CM T-cells correlates with the vaccination efficacy in
H-negative vaccinees.
Influenza-Specific Helper T-Cells Post
Vaccination Are Predominantly Recruited
From the Pre-existing Memory
Both serological groups showed efficient vaccination as reflected
by sufficient titers increase post vaccination (Table 1). The
influenza-specific T- and B-cells in the HI-positive group were
responsible for the sufficient cellular and humoral immunity
resulting in increased HI-titers. In the HI-negative group,
on the contrary, the role of the pre-existing cross-reactive
memory T-cells in the vaccination process was not clear
and for this reason we aimed to investigate to which extent
these pre-existing T-cells contributed to the formation of
influenza-specific T-cell memory as opposed to naive vaccine-
specific T-cells.
For this purpose, subsets of vaccine-specific T-cells based
on differentiation status were FACS-sorted at baseline and all
analysis points post vaccination. The T-cell receptor (TCR)
repertoires of all sorted populations were analyzed by sequencing
of the TCRβ chain on the nucleotide level. As T-cells originating
from the same progenitor bear identical TCR on the cell
surface, it can be used as a cellular identifier to track and
thus elucidate the origin of T-cells with different phenotypic
status, inter-subset dynamics and/or tissue distribution as
previously demonstrated (31, 32). In order to define the
origin of the influenza-specific CD4 T-cells post vaccination,
unique clonotypes from the sorted baseline naive or pre-
existing cross-reactive memory subsets (CM and Eff) were
tracked post vaccination at memory subsets and the cumulative
repertoire shares for the found clonotypes were calculated
(schematically shown in Figure 3A). The analysis revealed that
the influenza-specific clonotypes were predominantly recruited
from the pre-existing cross-reactive memory and that these
clonotypes constituted absolute majority of the vaccine-induced
helper T-cells. Tracking naive clonotypes from day 0 in post
vaccination repertoires revealed shared clonotypes of about
1% in only six out of 34 comparison pairs. The remaining
pairs showed either neglectable clonotype share or could
not reveal any single naive clonotype in post vaccination
memory (Figure 3B). The pre-existing cross-reactive memory,
on the contrary, contributed significantly higher to the post
vaccination repertoires constituting up to 80% of the memory
clonotypes (p < 0.001; Figure 3B). Based on these observations,
we conclude, that the influenza-specific helper T-cells are
predominantly recruited from the pre-existing cross-reactive
memory and not the naive repertoires.
Clonotype Diversity of Pre-existing
Influenza-Specific CM T-Cells Correlates
With the Serological Response
to Vaccination
Clonotype richness/diversity is a prerequisite for an antigen-
specific T-cell population to recognize broad array of pathogenic
epitopes, since T-cells targeting numerous epitopes are more
effective at combating the pathogens. To assess whether this
feature of influenza-specific T-cells played a role in the
vaccination efficacy we analyzed the correlation between the
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FIGURE 2 | Influenza-specific CD4 T-cells with CM phenotype define the vaccination efficacy in the serologically naive cohort. (A) Vaccine-specific helper T-cells were
analyzed in both serologically experienced (n = 7) and naive (n = 8) cohorts based on expression of CD154 and CD69, the cytokine-independent markers of
antigen-specific CD4 T-helper activation. Influenza-specific helper T-cells were further analyzed based on CCR7 and CD45RA allowing discrimination of cell with CM
(B), Eff (C), and naive phenotype (D). CM helper T-cells were defined as CCR7+CD45RA-, Eff as CCR7-CD45RA- and naive as CCR7+CD45RA+. Relative
frequencies among CD4 helper T-cells and absolute cell numbers per mL peripheral blood are shown. Parametric t tests with Holm-Sidak approach for multiple
comparisons were performed. The box plots show median with 25th to 75th percentiles and min to max range (whiskers). P-values are designated as following:
<0.05 as *, <0.01 as ** and <0.001 as ***. The applied gating strategy is provided in Figure S2. (E) Pearson correlation analysis of pre-existing vaccine-specific CD4
T-cells with CM phenotype in serologically unexperienced cohort at baseline (n = 8) analyzed as absolute cell numbers per mL peripheral blood and post-vaccination
antibody titer increase. R, Pearson correlation coefficient. The line represents the best linear fit.
clonotype richness and the antibody titer change in the HI-
negative group. As group size drastically influences diversity,
the analyzed samples were first normalized to equal size.
Next, sequence reads were grouped according to the clonal
identity and the number of unique clones was defined as a
measure of the sample richness. Our analyses revealed that
the baseline richness of influenza-specific CM helper T-cells
strongly correlated with serological outcome of vaccination in
the HI-negative group (Figure 4; Pearson R = 0.91, adjusted
p = 0.006). Clonotype diversity of further influenza-specific
populations and time points revealed no correlation to the
serology change. The detailed clonotype composition of CM
T-helper cell at baseline in HI-negative group is presented
in Table S2.
DISCUSSION
Influenza results in the formation of a long-term immunity that
can sometimes last lifelong (4, 37). Contacts with previously seen
epitopes lead to memory activation and fast pathogen clearance.
However, due to antigenic drift and shift new viral strains are
constantly created that can escape pre-existing antibodies and
T-cells. In this case the recruitment of naive T- and B-cells is
necessary for the efficient eradication of novel viruses. Not all
influenza virus components mutate with equal pace with HA
and NA showing the highest mutation rate (38, 39). This results
in a mixed immune response to both conserved and previously
unseen viral epitopes. For several pathogens, including influenza,
there are concerns that the pre-existing humoral and cellular
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FIGURE 3 | Post vaccination influenza-specific helper T-cell repertoires in the serologically unexposed group are formed predominantly from the pre-existing
cross-reactive memory and not the naive T-cells. In the HI-negative cohort influenza-specific clonotypes from the baseline naive and memory subsets (CM and Eff)
were tracked in the memory post vaccination and cumulative frequencies of the clonotypes with different origin (either naive or memory) were determined. (A)
Schematic representation of the performed analysis. Single clonotypes from naive and common pre-existing memory were tracked in post vaccination subsets;
cumulative frequencies of the corresponding clonotypes were estimated. (B) Cumulative frequencies of the influenza-specific clonotypes post-vaccination (n = 40)
originating from either naive (n = 6) or pre-existing cross-reactive memory subsets (n = 14) at baseline. *p < 0.05, **p < 0.01, and ***p < 0.001. Detailed information
on sorted cell populations and sequencing outcome is provided in Table S1.
FIGURE 4 | Clonotype richness of the cross-reactive vaccine-specific CM
T-cells at baseline significantly correlates with the level of serological response
to the previously unseen viral strains. Pearson correlation analysis between the
clonotype richness of influenza-specific CM CD4 T-cell subsets (n = 7) at
baseline and vaccination efficacy in the serologically unexperienced cohort.
Clonotype richness of the influenza-specific T-cells was assessed as the
number of unique clones per subset of normalized size (40,000 arbitrarily
sampled raw sequencing reads according to the size of the smallest analyzed
population). R, Pearson correlation coefficient. The line represents the best
linear fit.
immunity can hamper the response against novel strains and
skew the response against epitopes from previous encounters.
This phenomenon known as original antigenic sin (OAS) was
linked mostly to the pre-existing antibodies and described in
numerous infections, including influenza (31, 40–44). One of
the proposed mechanisms suggested the epitope masking by the
pre-existing antibodies resulting in the inhibited recruitment of
naive B-cells and skewed induction of memory B-cells from the
previous encounters (45–47). The role of helper T-cells in the
development of OAS in humans, however, was hardly addressed
due to sampling and technological limitations. Original data
from the Dengue virus and mouse LCMV studies pointed out
on the cross-reactive T-cell memory among the reasons of the
failed immunity (21, 22). Various animal studies confirmed this
concept (40, 41, 48). However, new data revealed CD4+memory
specific to highly conserved internal influenza virus proteins as a
protection correlate in human influenza infection (27).
Here, we analyzed the role of the pre-existing T-helper
memory in the vaccination against previously unseen influenza
strains. In order to exclude influence of immune senescence
on the vaccination efficacy and decrease the chance of previous
contacts with the vaccine strains, individuals younger than 65
were studied (49, 50). As the vaccine strains were previously
circulating, we first applied anamnestic approach to exclude cases
of overt infection as well as vaccination in the previous 3 years.
As half of the study participants revealed vaccine-specific titers,
these can be due to either subclinical/identified influenza or
contacts with the virus for longer than the defined time window.
Alternatively, this might reflect cross-reactive humoral immunity
as broadly cross-reactive antibodies against numerous influenza
strains were lately described (51, 52). Thus, final cohort definition
relied on baseline serological status and serologically naive group
was defined by absent vaccine-specific titers before vaccination.
The analysis of B-cell kinetics post vaccination revealed a
strong increase of PB frequencies. Though the antigen specificity
of the B-cell subsets was not assessed, the PB rise is most probably
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due to influenza-specific cells. It was previously shown, that up
to 80% of PB at day 7 post vaccination are vaccine-specific (35).
Furthermore, HI-positive cohort showed lower PB rise at the
peak of response as compared to HI-negative one. This might
be attributed to the pre-existing influenza-specific antibodies that
dampen influenza-specific B-cell responses post vaccination (34).
Still, even with lower PB increase the HI-positive group revealed
protective antibody titers.
Using multiparameter flow cytometry and NGS-based
clonotyping, we addressed the role of pre-existing helper T-cells
in the early process of vaccine-specific memory formation.
As MHC-class II tetramers are very limited and restrict cell
analysis to a handful of epitopes and HLA-allele, we applied
ex vivo stimulation and employed cytokine-independent
analysis of antigen-specific helper T-cells (36, 53). Of notice,
all subjects showed pre-existing memory T-cells at baseline,
both serologically exposed and unexperienced, suggesting
cross-reactive memory to conserved vaccine components and/or
third-party antigens. As split vaccine was used for stimulation of
influenza-specific T-cells, not only HA- and NA-specific but also
T-cells with other specificities (including internal proteins NP
and M1) were analyzed. The serology analysis utilizing HI-titers
focused on antibodies targeting HA-antigens as these antibodies
prevent hemagglutination induced by influenza hemagglutinins.
However, even though present before vaccination and included
into the analysis, the NP- and M1-specific T-cells (as well as
other specificities against conserved antigens) are very unlikely
to influence hemagglutinin-specific neutralizing titers as T- and
B-cell-specific epitopes must be physically linked for efficient
T-cell help (54, 55). In fact, it would be interesting to further
clarify the influence of pre-existing NP- andM1-specific T-helper
cell as cytotoxic T-cell with these specificities were associated
with reduced influenza severity (13). Notably, memory T-helper
cells specific to third-party microbial/environmental antigens
were shown to be cross-reactive to influenza (as well as HIV) that
were boosted after vaccination. As newborns showed only naive
T-cells with these specificities it was linked to increased infection
vulnerability (56).
On the clonal level we showed that in the serologically
unexperienced group the vaccine-induced T-cells are recruited
mostly from the pre-existing cross-reactive T-cell memory.
Even though naive-derived T-cells also contributed to post
vaccine-induced response, the clonotype share of naive-
derived cells was neglectable as compared to pre-existing
memory. To our knowledge this is the first report comparing
contribution of pre-existing memory and naive T-cells in
influenza vaccination. Our findings are in line with recent
reports from animal LIV influenza vaccination showing that
the pre-existing cross-reactive CD8 T-cell memory hampered
recruitment of naive specificities (23, 57). Another study
suggested that the subdominant heterotypic CD8 clonalities
suppress naive precursors (58). Further mouse influenza studies
revealed that cross-reactive memory specific to conserved
epitopes inhibited expansion of naive specificities (25, 59).
Another very recent report on whole blood clonotype analysis
did not reveal significant clonotype changes after influenza
vaccination suggesting that only a limited number of T-cells
was recruited in the course of vaccination which was not visible
on a global scale (60). Our findings show that in serologically
unexperienced individuals, the pre-existing cross-reactive
T-cells provide sufficient help to naive B-cells. There is still a
small hypothetical possibility, that even with lacking HI-titers
low levels of HA-specific non-neutralizing antibodies were
present at baseline stemming from the cross-reactive memory
B-cells specific to close viral strains. These cross-reactive B-
cells would eventually develop highly neutralizing antibodies
through somatic hypermutation. However, regardless of the
source of HI-titers, either naive of cross-reactive memory
B-cells, the pre-existing T-cells are helpful in generating
protective antibody titers with no or limited recruitment of
naive T-cells.
We detected vaccine-specific T-cells with naive phenotype
not only at baseline but also in follow-up, a phenomenon
not unique to influenza. Recently, we reported on high
frequencies of A. fumigatus-specific helper T-cells with naive
phenotype (31). Even though Aspergillus represents a ubiquitous
pathogen that constantly tackles the immune system, the
substantial amount of fungus-specific T-cells still remain in
the naive pool. This “dispensability” of naive T-cells might
be another hint on sufficient help from the pre-formed
T-cell memory.
Our analysis revealed that the pre-existing influenza-
specific helper T-cells with CM phenotype at baseline strongly
correlate with the serological response. To our knowledge
this is the first report on the differentiation status of
influenza-specific CD4 T-cells and vaccination efficacy. The post
vaccination expansions of influenza-specific IFNg-producing T-
helper cells as measured by Elispot were shown to tightly
correlate with increase of neutralizing antibodies. However, no
correlation was found between serology and the pre-existing
cross-reactive T-cells at baseline (54, 61). Here, influenza-
specific T-cells were analyzed independently of cytokine-
producing capacities in with markers allowing analysis of
differentiation status.
Another, yet unresolved question is to which extent the
diversity of the antigen-specific T-cells is important for an
efficient immune response. Few reports addressed the role
of clonotype diversity of antigen-specific T-cells in immune
response and specifically influenza vaccination (62, 63). As
more diverse clonotypes cover higher array of antigens, this
should more efficiently target a pathogen. We showed strong
correlation between the richness of pre-existing influenza-
specific CM helper T-cells and the humoral response to
previously unseen influenza vaccine strains. To our knowledge
this is the first report on the repertoire diversity of pre-
existing influenza-specific T-cells and vaccination efficacy.
In line with our results are the data showing impaired
influenza-specific response by restricted diversity CD8 T-cells
in mouse model (64). Another indication on the role of
clonotype composition comes from the human CMV setting,
showing inverse correlation between the breadth of CMV-
specific clonotype and antibody titers (65). Our data are
strongly corroborated by the analysis of circulating follicular
T-helper cells (cTfh) in influenza vaccination that revealed
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strong correlation between an increased cTfh-clonality and
rise of peripheral plasmablast cells post vaccination (62).
However, no link between cTfh-clonality at baseline and
vaccination efficacy was found. As baseline cTfh encompass
limited specificities to previously encountered influenza strains,
further T-helper subsets with differing specificities join cTfh-
pool upon vaccination and provide efficient help to influenza-
specific B-cells.
Although the role of pre-existing T-cells in the generation
of sufficient humoral immunity needs further analysis, several
authors suggest that the pre-existing memory T-cells can be of
great practical importance in vaccination (66, 67). In mouse
models, immunization with inactivated influenza viruses in
the presence of cholera toxin was reported to increase cross-
reactivity and enhance levels of neutralizing antibodies (68).
Currently, numerous studies in humans try to piggyback
cellular immunity to standard vaccines (diphtheria, tetanus,
and pertussis) in order to improve vaccination efficacy in risk
groups (69–71).
One limitation of the current study is the lack of patients
with failed vaccination. Additional studies on a cohort with
low or no response to vaccine in scenarios with or without
pre-existing antibodies would help to elucidate the role of
pre-existing immunity, either beneficial or detrimental, in
this process.
Taken together, our study demonstrates an important role
of pre-existing memory T-cells in the generation of vaccine-
specific humoral immunity to previously unseen strains.
While naive vaccine-specific T-cells could be detected prior
and after vaccine application independently of serological
status, these cells were not recruited in the formation of
vaccine-specific cellular memory as demonstrated by NGS
and multiparameter flow cytometry. Our findings suggest
that T-cell memory from previous encounters with close
influenza strains provides sufficient help to naive B-cells specific
to previously unseen viral strains and that the extent of
previous encounters is beneficial in terms of vaccine-induced
antibody titers.
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